Potentially orally bioavailable prodrugs of the antiretroviral agent 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) were evaluated. Alkyl methyl carbamates were synthesized by alkylation of PMPA with the corresponding alkyl chloromethyl carbonate and N-alkyl chloromethyl carbamate reagents. The prodrugs were evaluated for in vitro antiviral activity in addition to chemical and enzymic stability. The inhibition of human immunodeficiency virus type 1 (HIV-1) strain IIIB replication in MT-2 cells by the carbonate prodrugs was found to be 2.S-S00-fold increased compared to PMPA. The alkyl methyl carbonates, except t-butyl methyl carbonate, had reasonable chemical stability at pH 2.2 and 7.4, but were rapidly converted to the corresponding monoester of PMPA in the presence of dog plasma. The alkyl methyl carbamate prodrugs such as N-t-butyl methyl carbamate were found to have high stability in vitro. Based on its chemical stability and good oral bioavailability, bis(POqPMPA (isopropyl methyl carbonate) was chosen as a clinical candidate.
Introduction
Acyclic nucleoside phosphonates, 9-(2-phosphonomethoxyethyl)adenine 1 (PMEA) and 9-[2-(phosphonomethoxy)propyl]adenine 2 (PMPA) (Fig. 1) have shown potent and selective activity against human immunodeficiency virus (HIV) and other retroviruses (Balzarini et al., 1991 (Balzarini et al., , 1993 Bronson et al., 1989; De Clercq et al,1989; Egberink et al., 1990; Pauwels et al., 1988) . Recently, it has been shown that PMPA was able to prevent completely simian immunodeficiency virus (SIV) infection in macaques even when treatment was initiated as late as 24 h after inoculation (Tsai et al., 1995) . In longterm treatment of SlY-infected newborn rhesus macaques, PMPA showed efficacy (Van Rompay et al., 1996) without toxic side effects when monitored for a period of 13 months. In addition to this prophylactic activity, PMPA has also shown efficacy against chronic SIV infection in macaques (Tsai et al., 1997) as well as feline immunodeficiency virus (FIV) infection (Myles MH, Bischofberger N & Hoover EA; Evaluation of 9-(2phosphonylmethoxypropyl)adenine antiviral therapy for acute feline immunodeficiency virus infection ; Third International Feline Retrovirus Research Symposium, Fort Collins, Col., USA, March 6-9,1996) in cats. In a Phase IIII human clinical study, PMPA given intravenously was safe and well tolerated and caused a 1.1log 10 reduction of the HIV RNA levels after only eight doses.
PMPA showed low oral bioavailability in animals (KC Cundy and JP Shaw, unpublished results), presumably because of the presence of two negative charges associated with the phosphonate moiety. In order to improve the oral absorption of PMPA, we evaluated several PMPA prodrugs for their pharmaceutical properties, including bioavailability.
Acyloxyalkyl esters of carboxylic acid, for example ampicillin (Sakamoto et al., 1983) , of phophonates, such as foscarnet (lyer et al., 1989; Farquhar et al., 1983; Srivastava & Farquhar, 1984) , and of PMEA (Barditch-Crovo et al., 1997; Cundy et al., 1994; Naesens etal., 1996; Srinivas etal., 1993 Srinivas etal., , 1994 Starrett etal., 1994) are known MN Arimilli ef 0/. to improve the oral bioavailability over that of the parent drug. In the case of PMEA, a large variety of prodrugs were evaluated and bis(POM)PMEA 3 was selected for clinical development and is currently in Phase II/III human clinical trials. However, pivaloyloxyalkyl esters generate pivalic acid during the release of the parent drug, which at high doses can potentially decrease carnitine levels (Abrahamsson et al., 1994 ; Lacy SA, Cundy KC & Hitchcock MJM; Evaluation of the sub chronic toxicity of oral prodrug of the anti-HlV nucleotide analog 9-(2-phosphonylmethoxyethyl) adenine (PMEA); National Society of Toxicology Meeting, Baltimore, Md, USA, March 5, 1997). Therefore, we turned our attention to evaluate alkyl methyl carbonate and N-alkyl methyl carbamate prodrugs of PMPA. Alkyl ethyl carbonate prodrugs of carboxylic acids, such as bacampicilin (Ikeda et al., 1984) are known in the literature. However, very limited information is available on the use of alkyl methyl carbonate and N-alkyl methyl carbamate promoieties (Safadi et al., 1993) for phosphates or phosphonates. This paper describes the synthesis, in vitro and in vivo evaluation of carbonate and carbamate prodrugs of PMPA.
Materials and Experimental Procedures
All reactions were carried out under a dry atmosphere of argon unless otherwise noted. All reaction solvents were anhydrous grade obtained. from Aldrich. High resolution mass spectra were performed by the Mass Spectrometry Laboratory, University of California at Berkeley (Calif., USA). Column chromatography was performed using 230-400 mesh silica gel. IH NMR spectra were recorded at 300 MHz and 31p NMR at 75 MHz and 1 values are 558 reported in hertz. Splitting patterns are designated as s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; br, broad peak; and dd, doublet of doublet. CDCl 3 was used as solvent in all NMR samples. Reaction solutions were dried over Na 2S04 or MgSO 4.
General procedure for alkyl chloromethyl carbonates 4a-g A solution of the alcohol (73 mmol) and chloromethyl chloroformate (Fluka; 6.23 mL, 70 mmol) in diethyl ether (150 mL) was cooled to O°C under argon. Pyridine (5.7 mL, 70 mmol) was added dropwise with stirring over 10 minutes. The solution was stirred at O°C for 1 h then , allowed to warm to room temperature and stirred for an additional 3 h. The ether solution was filtered washed with 1 M HCI, dried over MgS0 4 , filtered~nd then concentrated on a rotary evaporator. Brief application of 13.332 Pa (0.1 torr) vacuum gave the alkyl chloromethyl carbonates in 85-95% yields. General procedure for N-alkyl chloromethyl carbamates 4h and i To a solution ofchloromethyl chloroformate (46.5 mmol) in dichloromethane (CH 2CI2, 30 mL) were added the amine (46.6 mmol) and proton sponge (46.6 mmol). The reaction mixture was stirred for 18 h and then poured into a separating funnel containing cold 0.5 M HCI (100 mL). The CH2C~layer was separated and washed with water (100 mL twice) and then dried over Na 2S04 • Evaporation of the solvent left the chloromethyl carbamate as a clear liquid.
General procedure for the synthesis of PMPA alkyl methyl carbonate prodrugs Method A Compounds 5a and 5b were synthesized using this procedure. Anhydrous PMPA (16 mmol) and diisopropylethylamine (DIEA) (Hunig's base) (66 mmol) were placed in anhydrous DMF (50 mL). The chloromethyl ethyl carbonate (49 rnmol) was then added and the suspension heated to 50°C under argon with rapid mechanical stirring. After 1 h the reaction was clear and the temperature was lowered to 35°C and the reaction stirred for 48 h. The DMF was removed on a rotary evaporator, and the reaction partitioned between CH 2C12 and water.The CH 2Cl2 layer was dried over magnesium sulphate, filtered and concentrated on a rotary evaporator.The residuewas chromatographed on a silica gel column (150 g Si0 2). Elution with 10% isopropanol in CH 2C12 removed the less polar impurities. Further elution with a 20% mixture of the same solvents furnished the desired product. 
Method B
Compounds 5c-i were synthesized using this method with appropriate reagents 4c-i.
To a stirred suspension of PMPA (26 mmol) in DMF (100 mL) at 50°C triethylamine (TEA) (77.8 mmol) was added. The reaction mixture became homogeneous and chloromethyl carbonate (77:8 mmol) was added to the reaction mixture and stirred at 50°C (oil bath temperature) for 20 h. The solvents were removed under reduced pressure and the residue was chromatographed on a silica gel column. Elution with 10% isopropanol in CH 2C12 removed non-polar impurities. Further elution with the same solvent mixture furnished the prodrug. 
Synthesis of PMPA N-alkyl methyl carbamate prodrugs
Method B was employed for the synthesis of compounds 5h and 5i. The reaction time was extended to 3 days. 9- 
Antiviral assays
Antiviral assays conducted with MT-2 cells were carried out by a modified assay with 2,3-bis[2-methoxy-4ni tro-5 -sulphophenyl] -5 -[(phenylamino) -carbonyl]-2H-tetrazolium hydroxide (XTT). Briefly, 96-well plates were set up as described (Weislow et al., 1989) , except that assays were done in the absence of polybrene and the infection proceeded for 3 h rather than 1 h before seeding. At 5 days post-infection, XTT and Nmethylphenazonium methosulphate were added to each well for 1 h and then mixed and the plates read at 450 nm. Data were plotted and fitted to a curve with Deltagraph Professional Program. The 50% effective concentrations of the drugs were defined as those concentrations that reduced killing due to virus infection by 50%.
Partition coefficient
The determination of the partition coefficient (log P) was performed at room temperature in a l-octanol/aqueous phosphate buffer (10 mM, pH 6.5) system. The prodrugs were dissolved in 1-octanol that had been presaturated with the phosphate buffer. An equal volume of this solution was mixed with the phosphate buffer layer and agitated continuously for 2 h, prior to separation for analysis (centrifugation, serial dilution, and HPLC quantification). The partition coefficient was determined by taking the log of the drug concentration measured in the l-octanol layer divided by the drug concentration found in the aqueous layer. 560 
Solution stability
The pH 2.0 buffer was prepared from H 3P04 and HPO4 and pH 7,4 buffer was prepared from KH 2 P0 4 and~HPO4' Total buffer concentration was 100 mM and total ionic strength was adjusted to 0.3 M with KCl. The solution stability of the prodrugs (-100 !-lg mL-1) was studied at 3TC. Samples were analysed at specific time points by a stability-indicating HPLC method. The specific first-order rate constants (k obs ) were calculated from the slope of semilogarithmic plots of the remaining prodrug versus time.
HPLC method for chemical hydrolysis and partition coefficient studies
The HPLC studies were conducted using a C reversephase analytical column (15 cmx3.9 mm)~ith mean particle diameter of 5 urn, All analyses were performed with a linear step gradient at ambient temperature. Mobile phase A contained 5% acetonitrile in 20 mM potassium phosphate and mobile phase B contained 65% acetonitrile in 20 mM potassium phosphate. The gradient profile was 100% A until 5.0 min, then a linear gradient to 100% B by 23.0 min, returning immediately to 100% A with 1 mL min? flow rate. Total run time was 30 min.
Dog plasma stability
Metabolic stability studies were performed at a final drug concentration of 10 flg ml.? (in DMSO) a"ud in 90% biological fluid (Pooled dog plasma was obtained from Oread Laboratories, Lawrence, Kan., USA). All tubes were preincubated without the drug in a shaker bath at 3TC (New Brunswick Scientific, Edison, N.] ., USA) and 100 oscillations min? for 5 min. The drug solution was added to the test incubations, mixed and maintained at 3TC and 100 oscillations min'", Aliquots (50 !-lL) were withdrawn at 1, 30 and 60 min and quenched with 100 ul, of 0.1% TFA in acetonitrile. Quenched samples were centrifuged for 5 min at 14 000 r.p.mo' in an Eppendorf centrifuge 5402, and the supernatant was used directly for HPLC analysis.
HPLC analysis of dog plasma studies
The HPLC system comprised a Model P4000 solvent delivery system with a Model AS3000 autoinjector and a Model UV1000 detector (Thermo Separation, San Jose, Calif., USA). The column was a Zorbax RX-C18 (5 urn, 250x4.6 mm) (MAC-MOD, Chadds Ford, Pa., USA) equipped with a Brownlee RP-18 Newguard guard column (7 urn, 15x3.2 mrn) (Alltech, Deerfield, Ill., USA). The mobile phases were: A, 20 mM potassium phosphate buffer, pH 6.0; B, 65% acetonitrile in 20 mM potassium phosphate, pH 6.0. The gradient profile was a linear gradient to 100% B by 15.0 min, returning immediately to 100% A. The flow rate was 1.0 mL min! and the column temperature was maintained at 35°C by a column oven. Detection was by UV at 262 nm and the injection volume was 50 ilL.Total cycle time between injections was 22 min. The observed rate constant for degradation (k obs ) was determined from the slope of a plot of the natural logarithm of the peak area of the prodrug versus time of incubation (min). The apparent half-life (t 1/2 ) was calculated as 0.693Ik obs ' For samples with less than 5% degradation after 60 min incubation, the prodrug was considered stable.
Results

Chemistry
The carbonate prodrugs 5a-g were synthesized by alkylation of PMPA with the corresponding chloromethyl alkyl carbonate reagents 4a-g. The chloromethyl alkyl carbonate precursors were prepared by the addition of pyridine to a cold ethereal solution of chloromethyl chloroformate and the corresponding alcohol (Bohme & Budde, 1971) . Similarly, the carbamate prodrugs were made from the chloromethyl alkyl carbamate precursors 4h and 4i, which were obtained by reaction of chloromethyl chloroformate with the corresponding amine in the presence of proton Antiviral Chemistry & Chematherapy 8(6) sponge (see Methods), as depicted in Fig. 2 .
The synthesis of the carbonate prodrugs 5a-g was' achieved by the addition of chloromethyl alkyl carbonate The carbamate prodrugs 5h and 5i were made using a similar procedure. Bis(POM)PMPA 5j was synthesized by the alkylation ofPMPA with chloromethyl pivalate in the presence ofTEA (Fig. 2) .
Antiviral activity
The antiviral activities of the carbonates 5a, 5c-g, and carbamates 5h and 5i against HIV-l strain IIIB were determined in MT-2 cells and IC so (50% inhibitory concentration) and CC so (concentration which kills 50% of the cells)valueswere measured.The carbonate prodrugs Sa, Sc, Se, Sf and Sg exhibited increased potency (2.5-500fold) compared to PMPA (Table 1) . Although cytotoxicity of the prodrugs also increased, the selectivity indices were improved compared to PMPA. The t-butyl carbonate 5d exhibited only 2.5-fold increased activity over PMPA with reduced selectivity possibly due to poor chemical stability. The carbamate prodrugs 5h and 5i showed a decrease in activity, despite the presence of the lipophilic carbamate moiety. Bis(POM)PMPA Sj was previously reported (Srinivas et al., 1993 (Srinivas et al., , 1994 to be more potent compared to PMPA. The antiviral activity data indicate good permeability of alkyl methyl carbonate prodrugs into cells, possibly due to their increased lipophilicity. The partition coefficient values (Table 2 ) support this hypothesis, with all prodrugs being more lipophilic (log P=0.6-3.2) compared to PMPA (log P=-2.5). The carbamate prodrugs, however, showed poorer antiviral activity as their lipophilic promoieties may be stable toward cellular enzymes (see below).
In vitro stability studies
A prodrug should have reasonable chemical stability to 562 survive the formulation and storage conditions as well as the acidic pH associated with the gastrointestinal tract. Consequently, the chemical stability (Table 2) at pH 2.2 and 7.4, and the biological stability of these prodrugs in dog plasma were evaluated. For comparison, the half-lives ofbis(POM)PMEA 3 at pH 2.0 and 7.4 (40·C) were 46 hand 6 h, respectively. However, bis(POM)PMEA 3 has very low stability (<10 min) in human and rat plasma (Shaw & Cundy, 1993) . Bis(POM)PMEA 3 has demonstrated good oral bioavailability in monkeys (22-25%, Cundy et al., 1994) as well as in humans (30-40%, Barditch-Crovo et al., 1997) . Therefore, the bioavailability data of the carbonate prodrugs was compared with that of bis(POM)PMEA 3.
The kinetics for the degradation of all the prodrugs studied fit a first-order exponential decay. The phosphonate monoester was the major observed degradation product within the pH range studied. The chemical stabilities (half-lives of 6-9 h) of the carbonate prodrugs Sa-g (except Sd) are similar to bis(POM)PMEA 3 at pH 7.4, 37·C. At pH 2.2 they have greater stability (>150 h) except for Sd, which had a half-life of 0.4 h at both pH values. Bis(POM)PMPA 5j has half-lives of 14 hand 68 h at pH 7.4 and 2.2, respectively. The carbamate prodrugs 5h and 5i have reasonable chemical stability at pH 7.4 (1.8 and 13 h, respectively).
In the presence of dog plasma (Table 2) , all the carbonate prodrugs 5a-g are readily hydrolysed (11/2=20 min) to the corresponding monoester of PMPA, whereas the carbamate prodrug Sh is very stable (tl/ 2 >100 min) under similar conditions. Bis(POM)PMPA 5j has a half-life of 36 min in dog plasma.
The prodrugs Sa-h and 5j were evaluated. for their pharmacokinetic properties in dogs, and demonstrated good oral bioavailability (20-36%) OP Shaw, MN Arimilli, CU Kim, J Dougherty, A Mulato, R Oliyai, KC Cundy and N Bischofberger,unpublished results). t-Butyl carbamate 5h exhibited only 8.8% oral bioavailability as PMPA and about 10% as intact prodrug. Under similar conditions, PMPA has 20% oral bioavailabilityin dogs. In the case of carbonate prodrugs no metabolites were found other than PMPA.
Discussion
The carbonate prodrugs Sa-g exhibit increased antiviral activity, good chemical stability (especially at lower pH) and are rapidly converted to the corresponding monoesters of PMPA in the presence of plasma. The increased antiviral activity of the carbonate prodrugs 5a-g can be attributed to increased cellular permeation of the prodrugs followed by effective intracellular conversion to PMPA, which undergoes subsequent phosphorylation to the antivirally active diphosphate metabolite. It is unclear why selectivity is increased, however, this has also been previously noted with bis(POM)PMPA (Srinivas et al., 1993) .
In contrast, the carbamate prodrugs exhibit greater stability in the presence of plasma and are less active in tissue culture than either the carbonates or the parent PMPA. The greater enzymic stability of carbamate prodrugs may be the reason for their diminished activity, as they fail to undergo sufficient hydrolysis to PMPA intracellularly.
' Based on its stability, enhanced cellular permeability, solubility, efficacy, low toxicity [no toxic side effects were observed (Bischofberger et al., 1997, Fourth Conference on Retroviruses and Opportunistic Infections, Washington DC, USA,January 22-26 1997. Abstract 214) up to 45 mg kg-1 day? dose for 5 days], and improved oral bioavailability over PMPA, bis(POC)PMPA 5fwas selected for clinical development and is currently being investigated in a Phase IIII study for pharmacokinetics, safety and efficacy in HIV-infected individuals.
